Here are the S-3 shelf registrations from HeartSciences Inc. Warrant (HSCSW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow HSCSW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HSCSW filings page.
HeartSciences Inc. filed a shelf prospectus covering up to $200,000,000 of common stock, preferred stock, debt securities, warrants, rights and units. Sales may occur only after the registration statement becomes effective and with a prospectus supplement; each offering’s amount and terms will be set in that supplement.
Until the earlier of the new registration statement’s effectiveness and March 27, 2027, HeartSciences may continue using its prior registration statement and supplements, including its at-the-market common-stock offering through or to Maxim as sales agent. The FDA cleared MyoVista wavECG on October 6, 2026 as a 12-lead resting electrocardiograph, but the clearance excludes an AI-ECG algorithm; commercializing the device with an impaired cardiac relaxation (e’) algorithm would require further development and separate FDA clearance. HeartSciences reported stockholders’ equity of $226,060 in its 2026 Annual Report, below Nasdaq’s $2,500,000 minimum. Nasdaq accepted its compliance plan, which identifies the proposed Fortitude merger, expected to close in Q4 2026, and gave the company until February 1, 2027 to evidence compliance.
HeartSciences Inc. is registering a shelf of up to $200,000,000 in an aggregate combination of common stock, preferred stock, debt securities, warrants, rights and units, for offerings from time to time. Specific pricing and terms will be provided in prospectus supplements, and sales cannot occur until the registration statement is effective. If sales generate net proceeds, the company intends to use them for working capital, capital expenditures and general corporate purposes, including research and development, regulatory work and merger-related expenses.
The prior registration and its Maxim at-the-market offering may continue until the new registration statement becomes effective or March 27, 2027, whichever occurs first. While the market value of non-affiliate common equity is below $75 million, Form S-3 primary sales are limited to one-third of that equity’s market value in any 12-month period.
HeartSciences says it needs additional funding and is directing resources principally to MyoVista Insights. Its MyoVista wavECG 510(k) submission remains under FDA review; the company recorded an approximately $0.3 million reserve against device inventory for the quarter ended July 31, 2026. The proposed Fortitude merger is expected to close in the fourth quarter of 2026.